肝动脉热灌注化疗栓塞治疗原发性肝癌临床观察

The clinical application of thermo-chemotherapy combined with TAE in the treatment of primary hepatic carcinoma

目的:观察热灌注化疗联合肝动脉栓塞(TAE)治疗原发性肝癌(PHC)的有效性及安全性。方法:78例PHC患者采用热灌注化疗联合TAE治疗,两次治疗间隔1个月,3个周期后,按照RECIST标准评价疗效及患者生活质量(QOL)。结果:术后3个月无CR患者,RR、DCR分别为39.7%和71.8%;术后3个月QOL改善、稳定和下降者分别为14、48和16例,改善率+稳定率为79.5%(62/78),无严重不良反应。结论:热灌注化疗联合TAE治疗PHC近期可以改善患者生活质量,提高治疗有效率及疾病控制率,且不良反应小,安全性好。

Objective：To investigate the efficacy and safety of recombinant thermal perfusion chemotherapy combined with transcatheter arterial embolization（TAE） on primary hepatic carcinoma（ PHC ）. Methods： Total of 78 cases of PHC were included. Every month repeated the treatment. After three therapeutic cycles, the clinical effect was evaluated with RECIST criteria and the living quality was assessed with Karnofsky scoring. Results： No CR patient. The RR and DCR were 39.7% and 71.8% respectively after 3 months. The QOL improvement, stability and decline patients were 14,48 and 16 respectively after 3 months. The improve rate ＋ stable rate was 79.5% （62/78）. There were no serious adverse events. Conclusion：Thermo - chemotherapy combined with TAE in patients with PHC can improve the quality of life and disease control rate. It is safe with few advense effect.